Agios shares rose after Saudi Arabia approved Pyrukynd for thalassemia under its breakthrough program. Retail defended the drug amid FDA concerns over 4 reported deaths, citing patient health conditions. Despite scrutiny, sentiment on Stocktwits turned 'bullish' with 'extremely high' activity. AGIO is up 13.6% YTD.